Generali Asset Management SPA SGR Lowers Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Generali Asset Management SPA SGR decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 36.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 7,666 shares of the biopharmaceutical company’s stock after selling 4,354 shares during the quarter. Generali Asset Management SPA SGR’s holdings in Regeneron Pharmaceuticals were worth $5,917,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. PGGM Investments lifted its stake in Regeneron Pharmaceuticals by 9.7% during the 3rd quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company’s stock valued at $52,057,000 after acquiring an additional 8,187 shares during the period. Sound Shore Management Inc CT purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $64,677,000. Rakuten Investment Management Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $33,121,000. Ellerson Group Inc. ADV raised its holdings in shares of Regeneron Pharmaceuticals by 49.2% during the third quarter. Ellerson Group Inc. ADV now owns 8,102 shares of the biopharmaceutical company’s stock valued at $4,556,000 after purchasing an additional 2,671 shares during the last quarter. Finally, Nordea Investment Management AB lifted its position in Regeneron Pharmaceuticals by 118.1% during the fourth quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock valued at $105,810,000 after purchasing an additional 74,350 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on REGN shares. Piper Sandler began coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 31st. They issued an “overweight” rating and a $875.00 target price on the stock. JPMorgan Chase & Co. boosted their target price on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $800.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, April 23rd. Sanford C. Bernstein cut their price objective on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a report on Wednesday, April 8th. Finally, Oppenheimer reiterated an “outperform” rating and set a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $826.59.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the sale, the senior vice president owned 4,272 shares in the company, valued at $3,325,837.44. This represents a 32.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the transaction, the director directly owned 17,503 shares in the company, valued at $12,343,815.72. This trade represents a 0.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 3,874 shares of company stock valued at $3,013,262. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.8%

Shares of REGN stock opened at $714.89 on Friday. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The stock has a market cap of $75.58 billion, a P/E ratio of 17.42, a P/E/G ratio of 1.58 and a beta of 0.30. The company has a 50 day simple moving average of $752.68 and a two-hundred day simple moving average of $740.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company’s revenue was up 19.0% compared to the same quarter last year. During the same quarter last year, the company posted $8.22 EPS. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 36.85 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.